爱沙尼亚生物库中处方激素避孕药使用趋势:纵向观察研究
本研究将2004至2022年处方激素避孕药购买数据与73,071名15-55岁女性使用者的遗传和健康数据结合,评估爱沙尼亚生物库是否适合研究激素避孕药副作用的遗传风险。结果显示64.2%使用者至少更换过一次配方,17.7%为快速更换者;5.3%携带至少一种血栓风险变异,携带者血栓发生率6.5%高于非携带者4.2%(OR=1.61,95%CI [1.40, 1.84],p<0.001)。
要点
- 爱沙尼亚生物库可用于研究激素避孕药副作用的遗传风险。
- 64.2%使用者至少更换过一次配方,17.7%为快速更换者。
- 血栓相关变异携带者血栓发生率6.5%,非携带者4.2%。
核心结论
- 爱沙尼亚生物库拥有稳健数据集,可用于研究遗传因素对激素避孕药副作用和疾病风险的影响。
研究设计与样本
- 纵向描述性研究,结合2004至2022年处方激素避孕药购买数据与73,071名15-55岁女性使用者的遗传和健康数据。
主要发现
- 19年间使用了20种激素避孕药配方和五种给药途径。
- 15-29岁使用者中最常用复方激素避孕药,孕激素-only使用随年龄和时间增加。
- 64.2%(n=46,920)使用者至少更换过一次配方,17.7%(n=12,929)为快速更换者。
- 快速更换者中23.1%(n=2,982)有副作用相关诊断,最常见为月经过多/不规则出血。
- 5.3%(n=3,886)使用者携带至少一种血栓风险变异,携带者血栓发生率6.5%高于非携带者4.2%(OR=1.61,95%CI [1.40, 1.84],p<0.001)。
临床怎么用
- 识别出的激素避孕药使用者特征为快速更换和停药的遗传分析提供框架。
- 该方法可在其他生物库中复制以验证发现。
局限性
- 使用行政药物购买记录,可能不反映实际激素避孕药使用。
- 激素避孕药使用期间附近的诊断可能不代表真实副作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hormonal contraceptives (HCs) are widely used and have well-documented population-level statistics. Previous studies with short follow-ups have focussed on individual HC use and side effects. However, the same aspects over longer periods, HC formulation switching, and the impact of genetic factors on HC side effects remain understudied due to the limited availability of suitable datasets. We investigated whether the Estonian Biobank (EstBB) is suitable for studying genetic risk for HC side effects. METHODS AND FINDINGS: This is a longitudinal descriptive study combining prescribed HC purchase data collected from 2004 to 2022 with genetic and health data from 73,071 female EstBB HC users aged 15-55 at the time of purchase. HC usage was defined by the Anatomical Therapeutic Chemical (ATC) codes G02B, G03A, and G03HB01. Methods included calculating age-stratified annual user prevalence, inferring usage periods from purchases, assessing formulation switching, identifying the International Classification of Diseases, Tenth Revision (ICD-10)-based side effect-related diagnoses and thromboembolism risk factors, and assessing carrier status for Factor V Leiden (FVL, rs6025) and prothrombin G20210A (PTM, rs1799963) genetic variants as proof-of-concept. Over 19 years, 20 HC formulations with five administration routes (oral pills, transdermal patches, vaginal rings, subdermal implants, intrauterine devices) were used. In the EstBB, combined HCs were the most commonly used among users aged 15-29, while progestin-only HC use increased with age and over time, comparable to the Estonian population. Overall, 64.2% (n = 46,920) of users switched formulations at least once, with 17.7% (n = 12,929) being rapid switchers. Side effect-related diagnoses were observed in 23.1% (n = 2,982) of rapid switchers, with excessive/irregular menstrual bleeding being the most common. Genetic analysis revealed that 5.3% (n = 3,886) of users carried at least one variant previously associated with increased thrombosis risk (3.5% (n = 2,556) carried FVL only, 1.8% (n = 1,276) PTM only, and 0.07% (n = 54) both). Carriers of thrombosis-associated variants had a significantly higher percentage of thrombosis (6.5%) than non-carriers (4.2%; OR = 1.61, 95% CI [1.40, 1.84], p < 0.001). The study is limited by the use of administrative medication purchase records, which may not reflect actual HC use. Additionally, diagnoses identified near the HC usage period may not represent true side effects. CONCLUSIONS: This study provides insights into real-world HC usage with longitudinal, individual-level detail that is not available in population-level statistics. We show that EstBB has a robust dataset for studying the impact of genetic factors on HC side effects and disease risk. The identified HC user profiles offer a framework for genetic analyses of HC rapid switching and discontinuation. Our approach can be replicated in other biobanks to validate findings across populations.
引用
- Džigurski J, Möls M, Läll K, et al. Prescribed hormonal contraceptive use trends in the Estonian Biobank: A longitudinal observational study. PLoS Med. 2026. PMID: 42160370. doi:10.1371/journal.pmed.1005086
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。